NASDAQ:URGN Urogen Pharma Q2 2026 Earnings Report $40.45 -0.43 (-1.05%) Closing price 07/29/2026 04:00 PM EasternExtended Trading$40.68 +0.23 (+0.56%) As of 07:16 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Urogen Pharma EPS ResultsActual EPSN/AConsensus EPS -$0.27Beat/MissN/AOne Year Ago EPSN/AUrogen Pharma Revenue ResultsActual RevenueN/AExpected Revenue$63.55 millionBeat/MissN/AYoY Revenue GrowthN/AUrogen Pharma Announcement DetailsQuarterQ2 2026Date8/6/2026TimeBefore Market OpensConference Call DateWednesday, August 5, 2026Conference Call Time10:00AM ETConference Call ResourcesEarnings HistoryCompany Profile Urogen Pharma Earnings HeadlinesUroGen Pharma to Report Second Quarter 2026 Financial Results on Wednesday, August 5th, 20263 hours ago | markets.businessinsider.comUrogen Pharma (NASDAQ:URGN) Receives Average Recommendation of "Moderate Buy" from BrokeragesJuly 29 at 2:15 AM | americanbankingnews.comALT SL: New Patent Reveals Elon Musk’s Next Breakthrough: M.A.G.I.Jeff Brown and Marc Chaikin - two investors who spotted Nvidia a decade ago - are now pointing to Elon Musk's latest AI patent as the catalyst behind their next major call. They say a market pattern with a 100% historical track record is converging with this new breakthrough by end of month. The last time conditions aligned like this, investors had the chance to turn $10,000 into as much as $350,000 in roughly 12 months. Brown and Chaikin have released the full details for investors who want to get ahead of it.July 30 at 1:00 AM | Brownstone Research (Ad)UroGen Pharma: Reimbursement Is Turning Zusduri Into A Workflow MoatJuly 20, 2026 | seekingalpha.comAnalysts Offer Insights on Healthcare Companies: Rani Therapeutics Holdings (RANI), Urogen Pharma (URGN) and vTv Therapeutics (VTVT)July 17, 2026 | theglobeandmail.comShort sellers are betting against UroGen Pharma stock, but Wall Street expects 263% earnings growth in 2027July 17, 2026 | msn.comSee More Urogen Pharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Urogen Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Urogen Pharma and other key companies, straight to your email. Email Address About Urogen PharmaUrogen Pharma (NASDAQ:URGN) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists. The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer. Jelmyto represents the first FDA-approved therapy for this indication, offering a minimally invasive, kidney-sparing alternative to surgery. Beyond Jelmyto, UroGen’s pipeline includes UGN-102, an investigational mitomycin solution under study for interstitial cystitis/bladder pain syndrome, and earlier-stage programs targeting other urologic and ophthalmic conditions leveraging the RTGel platform. UroGen markets its products primarily in the United States and is pursuing regulatory submissions in Europe and other global regions. The company’s management team is led by Co-Founder and Chief Executive Officer Tomer Kariv, supported by Chief Operating Officer Vas Narasimhan and Chief Medical Officer Philip Isaacs, among others. UroGen collaborates with key opinion leaders in urology to advance its clinical programs and expand patient access to novel in-office therapies.View Urogen Pharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Why SK hynix Could Be the Best AI Chip Stock to Buy NowWhy Bloom Energy May Be the Most Important AI Infrastructure StockAlphabet Is Down 18% From Its High After a Stellar Quarter—Overdone, or More Downside Ahead?Seagate Technology Stock Surges as Earnings Beat Silences AI DoubtersCarrier Earnings Could Send the Stock to a New All-Time High3 Refiners Benefiting From Oil Volatility and Tight Fuel SupplyWelltower at 52-Week Highs—But Analysts Believe There's More to Come Upcoming Earnings Linde (7/31/2026)Keysight Technologies (7/31/2026)Colgate-Palmolive (7/31/2026)Chevron (7/31/2026)Enbridge (7/31/2026)ExxonMobil (7/31/2026)NatWest Group (7/31/2026)Sumitomo Mitsui Financial Group (7/31/2026)Eaton (7/31/2026)AbbVie (7/31/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
